Skip to contentpdufa.bio

APL-101 (vebreltinib)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

APL-101 (vebreltinib) is an Apollomics Inc. program. Its next catalyst is a Readout in Jan 2027.

APLM catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Apollomics Inc. (APLM). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jan 2027APLM

Questions

When is APL-101 (vebreltinib)'s next FDA decision or readout?

The next tracked catalyst for APL-101 (vebreltinib) is a Readout in Jan 2027.

What happened at APL-101 (vebreltinib)'s most recent FDA decision?

No FDA decision for APL-101 (vebreltinib) is in our archive yet.

Who makes APL-101 (vebreltinib)?

Apollomics Inc. (APLM).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.